Role of Maraviroc in minimizing the risk of graft rejection in HIV‐infected kidney transplant recipients

2020 ◽  
Vol 22 (4) ◽  
Author(s):  
Gaetano Alfano ◽  
Giovanni Guaraldi ◽  
Francesco Fontana ◽  
Erica Franceschini ◽  
Giovanni Dolci ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Graft Rejection ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Extracorporeal photopheresis for the treatment of graft rejection in 33 adult kidney transplant recipients

2019 ◽  
Vol 58 (4) ◽  
pp. 515-524
Author(s):  
Mathilde Tamain ◽  
Johnny Sayegh ◽  
Arnaud Lionet ◽  
Philippe Grimbert ◽  
Carole Philipponnet ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Graft Rejection ◽  
Extracorporeal Photopheresis ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Adult Kidney

scholarly journals Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Aziza Ajlan ◽  
Hassan Aleid ◽  
Tariq Zulfiquar Ali ◽  
Hala Joharji ◽  
Khalid Almeshari ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
De Novo ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
First Year ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Double Blind ◽  
Donor Specific Antibodies

Abstract Background Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated. Aims To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC protocol. Methods Prospective, randomized, double blind, non-inferiority, controlled clinical trial Expected outcomes 1. Primary outcomes: Biopsy-proven acute rejection within first year following transplant 2. Secondary outcomes: a. Patient and graft survival at 1 year b. eGFR at 6 months and at 12 months c. Emergence of de novo donor-specific antibodies (DSAs) Trial registration The study has been prospectively registered at clinicaltrials.gov (NTC: 04404127). Registered on 27 May 2020.

Role of induction therapy in low immunological risk-kidney transplant recipients: A mate-kidney analysis

2019 ◽  
pp. e13442 ◽  
Author(s):  
Kalathil K. Sureshkumar ◽  
Vinaikumar Katragadda ◽  
Bhavna Chopra ◽  
Marcelo Sampaio
Keyword(s):  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Role of the Early Association of a mTOR Inhibitor and Tacrolimus in BK Polyomavirus Infection in Kidney Transplant Recipients

2018 ◽  
Vol 102 ◽  
pp. S566
Author(s):  
Veronica Lopéz ◽  
Teresa Vazquez ◽  
Cristina Jironda ◽  
Mercedes Cabello ◽  
Juana Alonso ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Mtor Inhibitor ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Bk Polyomavirus

The role of single nucleotide polymorphisms of CYP3A and ABCB1 on tacrolimus predose concentration in kidney transplant recipients

2017 ◽  
Vol 88 (S1) ◽  
pp. 115-118 ◽  
Author(s):  
Gregor Mlinšek ◽  
Vita Dolžan ◽  
Katja Goričar ◽  
Jadranka Buturović-Ponikvar ◽  
Miha Arnol
Keyword(s):  
Single Nucleotide Polymorphisms ◽  
Kidney Transplant ◽  
Nucleotide Polymorphisms ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Single Nucleotide
Sign in / Sign up

Export Citation Format

Share Document